Drug & supplement interaction

Mesoglycan + Inotuzumab Ozogamicin

Inotuzumab Ozogamicin brand name: Besponsa.

No Known Interaction
Medically reviewed by · Updated July 2026 · Pair last verified Sep 13, 2026
The bottom line No known interaction

We found no known interaction between Mesoglycan and Inotuzumab Ozogamicin in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share
Facebook Post Reddit Email
On this page
Interaction report

Mesoglycan and Inotuzumab Ozogamicin

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Inotuzumab Ozogamicin and Mesoglycan in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Mesoglycan safety at a glance

Mesoglycan overall Use caution Generally tolerated in studies, but it can affect blood clotting and lacks long-term safety data.
Pregnancy Avoid There is not enough safety information, so it is best avoided during pregnancy.
Breastfeeding Avoid Safety while breastfeeding is unknown, so avoid use.

Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Inotuzumab Ozogamicin and Mesoglycan? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
How we checked

Why No Interaction Is Listed for Inotuzumab Ozogamicin

Interactions in our licensed database are recorded against drug classes, not just single drug names. Inotuzumab Ozogamicin is filed under a single classification — qt interval-prolonging drugs. Mesoglycan has documented interactions with 2 drug classes — the most serious being anticoagulant/antiplatelet drugs (moderate) and thrombolytic drugs (moderate) — and none of Inotuzumab Ozogamicin’s classifications are among them.

Classification data comes from our licensed Natural Medicines dataset. A medication can belong to classes beyond those recorded there, so this describes how the check was run — it is not a safety guarantee.

Keep it in perspective

Mesoglycan Does Interact With Other Medications

Mesoglycan has 122 moderate known drug interactions in our database — Inotuzumab Ozogamicin isn’t one of them. If you take anything else, check it against the full list below.

Moderate 122 No known interaction 2,708 (incl. Inotuzumab Ozogamicin)
Taking anything else?

Check Another of Your Medications Against Mesoglycan

Covers the 2,830 medications we’ve checked against Mesoglycan. Pick one to open its full report.

What to actually watch for

No Interaction Found — But Data Suggests Mesoglycan and Inotuzumab Ozogamicin May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do.

  • Stomach upset / Diarrhea / Vomiting / Nausea Additional detail

    Mesoglycan

    “Orally, mesoglycan seems to be well tolerated. Some adverse effects reported in clinical studies include nausea, vomiting, epigastric pain, dyspepsia, heartburn, headache, diarrhea, and local cutaneous reactions.

    However, there is some concern about potential contamination. Mesoglycan is derived from raw animal tissues gathered from slaughterhouses, possibly from sick or diseased animals.”

    Mesoglycan · Natural Medicines adverse-effect record, reported in cluster headache.

    6 sources cited
    1. 6629. Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol 1997;45:383-92.
    2. 97778. Viliani T, Scarselli M, Pieri A, Gatti M, Santini M, Pasquetti P. Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan. Eur J Phys Rehabil Med. 2009;45(1):21-9.
    3. 97779. Gossetti B, Antignani PL, Jabbour J, Martinelli O. Flow-mediated dilation benefits of mesoglycan in peripheral artery disease. Int Angiol. 2015;34(4):398-406.
    4. 103265. Valvano A, Bosso G, Apuzzi V, Riccone F, Saccá L, Oliviero U. Mesoglycan improves vascular reactivity and insulin sensitivity in patients with metabolic syndrome. Atherosclerosis. 2015;243(2):407-13. PubMed
    5. 6620. Nationwide alert on hallmark labs injectable adrenal cortex extract. FDA. Available at: www.fda.gov/bbs/topics/NEWS/NEW00539.html
    6. 1825. Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.

    “Orally, mesoglycan has been reported to cause nausea, vomiting, epigastric pain, dyspepsia, heartburn, and diarrhea.”

    Mesoglycan · Natural Medicines adverse-effect record, reported in diarrhea.

    3 sources cited
    1. 6629. Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol 1997;45:383-92.
    2. 97779. Gossetti B, Antignani PL, Jabbour J, Martinelli O. Flow-mediated dilation benefits of mesoglycan in peripheral artery disease. Int Angiol. 2015;34(4):398-406.
    3. 103265. Valvano A, Bosso G, Apuzzi V, Riccone F, Saccá L, Oliviero U. Mesoglycan improves vascular reactivity and insulin sensitivity in patients with metabolic syndrome. Atherosclerosis. 2015;243(2):407-13. PubMed

    Inotuzumab Ozogamicin

    Listed in the ADVERSE REACTIONS section of the FDA label for Inotuzumab Ozogamicin. Read the label on DailyMed ›

  • Swelling Additional detail

    Mesoglycan

    “Orally, mesoglycan has been reported to cause local cutaneous reactions.

    Subcutaneously, injections of mesoglycan into the scalp were thought to result in edema, redness, and local hair loss in a 32-year-old female.”

    Mesoglycan · Natural Medicines adverse-effect record, reported in alopecia.

    1 source cited
    1. 97780. Duque-Estrada B, Vincenzi C, Misciali C, Tosti A. Alopecia secondary to mesotherapy. J Am Acad Dermatol. 2009;61(4):707-9. PubMed

    Inotuzumab Ozogamicin

    Listed in the ADVERSE REACTIONS section of the FDA label for Inotuzumab Ozogamicin. Read the label on DailyMed ›

  • Headache Additional detail

    Mesoglycan

    “Orally, mesoglycan has been reported to cause headache.”

    Mesoglycan · Natural Medicines adverse-effect record, reported in cluster headache.

    1 source cited
    1. 6629. Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol 1997;45:383-92.

    Inotuzumab Ozogamicin

    Listed in the ADVERSE REACTIONS section of the FDA label for Inotuzumab Ozogamicin. Read the label on DailyMed ›

Reported for Mesoglycan but not commonly for Inotuzumab Ozogamicin: heartburn and hair loss.

Effects for Inotuzumab Ozogamicin come from the ADVERSE REACTIONS section of its FDA label; effects for Mesoglycan come from the Natural Medicines adverse-effect record, quoted above. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Everything else you take

See Every Supplement That Interacts With Inotuzumab Ozogamicin

This page covers Mesoglycan only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Inotuzumab Ozogamicin page lists 13 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: American Hellebore (major), Arsenic (major), Cesium (major), Ephedra (major) and Grapefruit (major).

By severity: 6 major · 7 moderate.

From our pharmacist’s overview on the Inotuzumab Ozogamicin page

“Every supplement on this page interacts with inotuzumab ozogamicin (Besponsa) in the same way, by adding to the drug's own known tendency to prolong the QT interval, the heart's electrical reset time, which raises the risk of dangerous rhythm problems. Besponsa is chemotherapy for a form of acute leukemia, so my advice is to clear any…”

Reviewed by 2 · Jul 18, 2026

Open the Inotuzumab Ozogamicin interaction page

How much people look this up

Where Mesoglycan and Inotuzumab Ozogamicin Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Mesoglycan
Top half

#541 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication Inotuzumab Ozogamicin
Top half

#972 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Mesoglycan reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Mesoglycan and Inotuzumab Ozogamicin records this page draws on were last updated July 10, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Supplement

About Mesoglycan

What is Mesoglycan?

  • Vein health and chronic venous insufficiency
  • Leg ulcers
  • Peripheral artery disease and leg pain
  • Reducing blood clot risk
  • Hemorrhoids

Mesoglycan is a blend of natural sugar-protein compounds (glycosaminoglycans, including heparan sulfate and dermatan sulfate) taken from animal tissue and used mainly for blood vessel and circulation problems. Some small studies suggest possible benefit for vein-related conditions, but the overall evidence is limited and not strong. Because it can affect blood clotting, talk to your doctor or pharmacist before using it.

Glycosaminoglycans extracted from porcine (pig) intestinal mucosa · Tablets, capsules

An interaction check asks whether these two react with each other — it does not ask whether Mesoglycan is a good idea for someone in your situation. Here is what our Mesoglycan record says about it on its own.

Mesoglycan: dosing

There is no official, standardized dose of mesoglycan, and products can differ from one another. In studies it has been given by mouth in divided daily doses, and sometimes by injection in medical settings.If you use a mesoglycan product, follow the directions on the label and do not exceed the recommended amount.

From our Mesoglycan monograph — the full record covers uses, side effects and every documented interaction.

Read the full Mesoglycan monograph & all interactions
Medication

About Inotuzumab Ozogamicin Injection

What Is Inotuzumab Ozogamicin Injection Used For?

Brand name: Besponsa

Besponsa is approved to treat relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) — a type of blood cancer that has come back or has not responded to previous treatment. It is approved for both adult and pediatric patients 1 year of age and older.

ALL is a fast-moving cancer of the blood and bone marrow. Besponsa specifically targets leukemia cells that carry a protein called CD22 on their surface, making it a targeted therapy rather than a general chemotherapy.

See full Inotuzumab Ozogamicin Injection drug information
Keep checking

Other Drugs & Mesoglycan

Browse every other medication we’ve checked against Mesoglycan — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
122Moderate
0Minor
2,707No known interaction
122 Moderate 2,707 No interaction
Moderate

122 interactions

Showing 60 of 122 moderate interactions — see all 122 on the Mesoglycan page.

No interaction 2,707 drugs checked — show the list

We also checked Mesoglycan against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 2,707 medications checked with no known interaction — see the full Mesoglycan list.

See the full Mesoglycan interactions page
See every supplement checked against Inotuzumab Ozogamicin, ranked by severity
Evidence & sources

Mesoglycan References

The 26 references that drive our Mesoglycan monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Lewis CJ. Letter to reiterate certain public health and safety concerns to firms manufacturing or importing dietary supplements that contain specific bovine tissues. FDA. Available at: www.cfsan.fda.gov/~dms/dspltr05.html.
  2. Nationwide alert on hallmark labs injectable adrenal cortex extract. FDA. Available at: www.fda.gov/bbs/topics/NEWS/NEW00539.html
  3. Laurora G, Cesarone MR, Belcaro G, et al. [Control of the progress of arteriosclerosis in high risk subjects treated with mesoglycan. Measuring the intima media]. Minerva Cardioangiol 1998;46:41-7.
  4. Raso AM, Maggio D, Trogolo M, et al. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol]. Minerva Cardioangiol 1997;45:383-92.
  5. Blardi P, Messa G, Puccetti L, et al. [Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man]. Recenti Prog Med 1995;86:282-9.
  6. Lotti T, Celasco G, Tsampau D, et al. Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis. Int J Dermatol 1993;32:368-71. PubMed
  7. Ambrosio LA, Marchese G, Filippo A, et al. The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation. J Int Med Res 1993;21:138-46. PubMed
  8. Orlandi G, Viapiano F, Massetani R, et al. Clinical-instrumental evaluation of the effects of mesoglycan sulphate in chronic vascular encephalopathy. Acta Neurol (Napoli) 1991;13:255-60.
  9. Abate G, Berenga A, Caione F, et al. [Controlled multicenter study on the therapeutic effectiveness of mesoglycan in patients with cerebrovascular disease]. Minerva Med 1991;82:101-5.
  10. Prandoni P, Cattelan AM, Carta M. [Long-term sequelae of deep venous thrombosis of the legs. Experience with mesoglycan]. Ann Ital Med Int 1989;4:378-85.
  11. Cazzato G, Zorzon M, Mase G, et al. [Mesoglycan in acute focal cerebral ischemia]. Riv Neurol 1989;59:121-6.
  12. Vittoria A, Messa GL, Frigerio C, et al. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses. Int J Tissue React 1988;10:261-6.
  13. Postiglione A, De Simone B, Rubba P, et al. Effect of oral mesoglycan on plasma lipoprotein concentration and on lipoprotein lipase activity in primary hyperlipoproteinemia. Pharmacol Res Commun 1984;16:1-8. PubMed
  14. Arosio E, Ferrari G, Santoro L, et al. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg 2001;22:365-72. PubMed
  15. Nenci, G. G., Gresele, P., Ferrari, G., Santoro, L., and Gianese, F. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb.Haemost. 2001;86(5):1181-1187. DOI

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Mesoglycan and Inotuzumab Ozogamicin Together: Common Questions

Is it safe to take Mesoglycan with Inotuzumab Ozogamicin?
We do not list a known interaction between Mesoglycan and Inotuzumab Ozogamicin. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Mesoglycan and Inotuzumab Ozogamicin have any of the same side effects?
Yes — our sources link each of them separately to 6 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
How was the Mesoglycan and Inotuzumab Ozogamicin combination checked?
Interactions in our licensed database are recorded against drug classes. Inotuzumab Ozogamicin is filed under 1 classification, and Mesoglycan has documented interactions with 2 drug classes — none of Inotuzumab Ozogamicin's classifications are among them. A medication can belong to classes beyond those recorded in our dataset, so this describes how the check was run rather than guaranteeing safety.
Does Mesoglycan interact with any other medications?
Yes. Mesoglycan has 122 documented drug interactions in our database — Inotuzumab Ozogamicin is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.
Does Inotuzumab Ozogamicin interact with any supplements?
Yes. Inotuzumab Ozogamicin has documented interactions with 13 supplements in our database — Mesoglycan is not one of them. The Inotuzumab Ozogamicin interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Mesoglycan monograph Uses, safety profile, and every drug interaction in one place Inotuzumab Ozogamicin Injection drug information The full plain-English guide to this medication Inotuzumab Ozogamicin supplement interactions Every supplement checked against Inotuzumab Ozogamicin, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 26 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About Inotuzumab Ozogamicin and Mesoglycan?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.